chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Five hours after injection I broke out into hives on my wrists/forearms, ankles, inner thighs, and armpit. I went to urgent care the next morning and got steroids and the rash subsided after a few days. The itchiness lingered until September 13, (vaccine was given 6/4) when I broke out in the same rash but this time my ankles became very red and very very swollen. The rash was both painful and itchy. I returned to urgent care to revive steroids and again after several days (4-5) the rash subsided bit itchiness lingering. I broke out a third time the first week of October but this time a home rememdy of 2000 IUs of Vitamin D and garlic pills both taken twice daily were able to help the rash subside. Benedryl and hydrocortisone did not do much to help. Hydrocortisone helped somewhat soothe the intensity but didn?t help a whole lot and if I took more than two benedryl it would also soothe symptoms mildly but if only taken one or two benedryl, the rash seemed to worsen. The rashes when present would appear in the evening, get less intense over night, and progressively grow in intensity until fully flared before bedtime. This pattern would repeat until treated.   Also during this time, beginning after my first rash, I was on my period for THREE MONTHS. It was very light for the most part but I am 30 years old and have never had an irregular period in my adult life. Things resolved the second week of October but it is a October 16th and I?m sure issues will continue.
Within 15-minutes of vaccination, the patient reported fatigue and feeling "sleepy". EMS monitored patient's condition on-site.
some pain at the injection site; This is a spontaneous report from a contactable other healthcare professional via Pfizer sales representative. A female patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiration date not reported), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient experienced some pain at the injection site after use of product. The outcome of event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Swelling of eyes & face with rash, burning & itching, also on my neck.
Swelling gland under the ear; Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of LYMPHADENOPATHY (Swelling gland under the ear) and PAIN IN EXTREMITY (Sore arm) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Feb-2021, the patient experienced LYMPHADENOPATHY (Swelling gland under the ear) and PAIN IN EXTREMITY (Sore arm). At the time of the report, LYMPHADENOPATHY (Swelling gland under the ear) and PAIN IN EXTREMITY (Sore arm) had resolved.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   Concomitant medication was not reported.  Treatment medication was not reported.   Most recent FOLLOW-UP information incorporated above includes: On 29-Apr-2021: Reporter said Everything is Fine now. Declined to share Email address
Swelling of ankles and ankle pain one week after 3rd dose(booster). Treated with 6 days of steroid by primary care doctor. Symptoms resumed after steroid with additional pain throughout the trunk and legs. Referred to Rheumatologist. 12 days steroid and pain resolved and resumed after steroids. Numbness pain and tingling began in late February. Additional steroid resolved pain. Numbness and tingling continued. Rheumatology referred to emergency room and neurology.  MRI of spine and spinal tap showed spinal inflammation and lesions. Hospital admission for 10 days. Received ivig and high dose steroid.  Diagnosis is transverse myelitis. Continued treatment with steroids, baclofen and pegabalin.  Numbness and tingling continues. Physical therapy prescribed. Symptoms remain as of current date.
My vision became blurry and I was unable to focus my eyes during the first 2 days when the symptoms began. I sought medical care on May 20th with my primary dare doctor, who recommended to monitor the symptoms for one week. As of this date my vision in my right eye is still blurry.
area is red & raised, temp, chills, malaise, wheezing; sx appeared day p/inject;
Fluarix exposed to freezing temperature was administrated; This case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a 47-year-old male patient who received Flu Seasonal QIV Dresden (Fluarix Quadrivalent 2021-2022 season) (batch number LZ4N2, expiry date 30th June 2022) for prophylaxis.   Co-suspect products included flu seasonal qiv dresden pre-filled syringe device (Fluarix Tetra Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 11th October 2021, the patient received Fluarix Quadrivalent 2021-2022 season and Fluarix Tetra Pre-Filled Syringe Device. On an unknown date, unknown after receiving Fluarix Quadrivalent 2021-2022 season and Fluarix Tetra Pre-Filled Syringe Device, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: It was reported that the Fluarix QIV that was exposed to freezing temperature was administrated to the patient, which led to incorrect storage of drug.  No symptoms or further details were reported.  The reporter agreed to be contacted for follow-up. This is one of eight cases reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR215097:Original Case : US2021214412 US-GLAXOSMITHKLINE-US2021AMR215096:Original Case : US2021214412 US-GLAXOSMITHKLINE-US2021AMR215095:Original Case : US2021214412 US-GLAXOSMITHKLINE-US2021AMR215094:Original Case : US2021214412 US-GLAXOSMITHKLINE-US2021AMR215093:Original Case : US2021214412 US-GLAXOSMITHKLINE-US2021AMR215098:Original Case : US2021214412 US-GLAXOSMITHKLINE-US2021AMR215092:Original Case : US2021214412
Injection site redness; Injection site swelling; Injection site warmth; This case was reported by a pharmacist via call center representative and described the occurrence of injection site erythema in a 53-year-old female patient who received Herpes zoster (Shingrix) (batch number 3FJ59, expiry date 27th November 2021) for prophylaxis.   On 14th September 2019, the patient received the 2nd dose of Shingrix. In September 2019, less than a week after receiving Shingrix, the patient experienced injection site erythema, injection site swelling and injection site warmth. On an unknown date, the outcome of the injection site erythema, injection site swelling and injection site warmth were unknown.   It was unknown if the reporter considered the injection site erythema, injection site swelling and injection site warmth to be related to Shingrix.  Additional case details were reported as follows: The patient received vaccine in left deltoid. The patient experienced injection site redness, warmth, and swelling. The healthcare professional reported the patient noticed the events two days later but could not provide an exact start date. The reporter consented to follow up.
This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Usual soreness at injection site) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 0261.20A) for COVID-19 vaccination.     The patient's past medical history included Stroke (Summer) in 2020. Concurrent medical conditions included Allergy NOS (Unspecified, takes eye drops), Chronic atrial fibrillation since 2011, Shellfish allergy, Hypothyroidism since 2010, Blood pressure high, Diabetes since 2020 and High cholesterol since 2020. Concomitant products included APIXABAN for Anticoagulant therapy, BISOPROLOL FUMARATE, HYDROCHLOROTHIAZIDE (BISOPROLOL /HCTZ) for Blood pressure high, METFORMIN for Diabetes, ATORVASTATIN for High cholesterol, LEVOTHYROXINE for Hypothyroidism.    On 26-Jan-2021 at 8:30 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jan-2021, the patient experienced VACCINATION SITE PAIN (Usual soreness at injection site). On 28-Jan-2021, VACCINATION SITE PAIN (Usual soreness at injection site) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       There was no acute illness at the time of vaccination and up to one month before. Concomitant products also included unspecified eye drops for allergy. Treatment information was not reported.   This case was linked to MOD-2021-049777 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 28-Apr-2021: Follow up received on 28-Apr-2021, Concurrent medications and medical history added. Concomitant medications added.Patient demographics updated.
Rash on feet and legs; This is a spontaneous report from a contactable healthcare professional, the patient. A 33-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FA7485) via an unspecified route of administration in the left arm on 04Aug2021 at 13:15 (at the age of 33-years-old) as a single dose for COVID-19 immunisation. Medical history included polycystic ovary syndrome, endometriosis and hysterectomy which was not ongoing. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. It was unknown whether the patient received any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications were not reported. The patient received amoxicillin; clavulanic acid (AUGMENTIN) on an unknown date and experienced allergy to antibiotic, also received varenicline tartrate (CHANTIX) and paracetamol; oxycodone hydrochloride (PERCOCET) on unknown dates and experienced drug allergy. The patient previously received first dose of (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FA6780) via an unspecified route of administration in the left arm on 14Jul2021 at 13:00 (at the age of 33-years-old), as a single dose for COVID-19 immunisation. On 05Aug2021, the patient experienced rash on feet and legs. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the reported event. The clinical outcome of the event rash on feet and legs was not resolved at the time of this report.
Yesterday, 2/17, I noticed a large (approx 5" circle) rash around my injection site. It is itchy, a bit firm, and a little swollen. I'm not certain as to when it started, just noticed it after a shower. No other symptoms.
Joint and muscle pain, headache, nausea, fatigue, shivering, sensitive skin
(+) Nausea, (+) fatigue, (+) UTI sxs.
pt recvd vax & exp n, general malaise, headache, sore throat & devel d & v; pt felt "quite ill" for 4 days;
Dozens of Raised Rash-like bumps on Right Leg Rash on Rt Leg from the Knee Down on inside of leg severe itch
Patient had his yearly well child exam on 9/5/18 along with DTaP, MMRV, Hep A the vaccine known as KINRIX was given in his left arm.
4hr p/vax pt devel shivers sent to ER-no sz activity noted, t102-d/c from ER
Client received DTaP IM and IPV SC in Left arm on 06-10-2004 in the A.M. On 06-11-2004 around 2-3 PM childs mother noted that the child had developed left upper arm reddness and swelling. She stated the left arm was 2 times larger than the right arm. The mother also stated that at 10 AM the child had gone swimming and the arm was ok at that time. Child was taken to the Emergency room and was put on Keflex for 10 days and also on pediatric benedryl. on 06-17-2004 the mother stated that the arm has improved but a small lump remains and that the ER doctor stated that the child had an allergic reaction to the vaccine and had a cellulitis.
Patient developed headache after second dose in series. Headaches increased in severity with subsequent doses.  With fifth dose, patient developed hives, sought care at physician's office.  Received diphenhydramine.  Hives cleared within next few hours.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 50-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 4 (booster), single (Batch/Lot number: unknown), in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Indication: Treatment of COVID-19. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical Information: Anti-viral details: Product: COVID 19 Treatment, Treatment start date: 28Aug2022, Treatment stop date: 01Sep2022.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
pt became weak and sweating,  passed out.  came to, and was sweating and weak and confused.
Patient had a small red area on chest as noted by mom. Patient given Benadryl and sent to the ER for observation.
Neck pain; Discomfort in the shoulder; dose was administered to the patient too high in the shoulder; Axillary pain; shoulder pain was worsening and having a hard time in moving it; This spontaneous case was reported by an other health care professional and describes the occurrence of NECK PAIN (Neck pain), MUSCULOSKELETAL DISCOMFORT (Discomfort in the shoulder), INCORRECT ROUTE OF PRODUCT ADMINISTRATION (dose was administered to the patient too high in the shoulder), AXILLARY PAIN (Axillary pain) and ARTHRALGIA (shoulder pain was worsening and having a hard time in moving it) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Other) 1 dosage form. On 12-Apr-2021, the patient experienced NECK PAIN (Neck pain), MUSCULOSKELETAL DISCOMFORT (Discomfort in the shoulder), INCORRECT ROUTE OF PRODUCT ADMINISTRATION (dose was administered to the patient too high in the shoulder), AXILLARY PAIN (Axillary pain) and ARTHRALGIA (shoulder pain was worsening and having a hard time in moving it). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 12-Apr-2021, INCORRECT ROUTE OF PRODUCT ADMINISTRATION (dose was administered to the patient too high in the shoulder) had resolved. At the time of the report, NECK PAIN (Neck pain), MUSCULOSKELETAL DISCOMFORT (Discomfort in the shoulder), AXILLARY PAIN (Axillary pain) and ARTHRALGIA (shoulder pain was worsening and having a hard time in moving it) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Other), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.
Initial case received from a healthcare professional, (nurse) on 23 October 2013. A 46-year-old female patient received a dose of IMOVAX (lot # H1512-3) into the right deltoid on 23 October 2013. It was reported that the patient received a previous dose of IMOVAX, details not reported. On 20 October 2013, the patient had received both RABIVERT, manufacturer Novartis, lot # 532011A into the left deltoid and RIG, manufacturer and lot number unknown into the bite wound into the hand, dose and route not reported. The patient has a history of allergies to PCN, sulfa, Aceti, clinda, DARVOCET, codeine. The patient had an allergy to a vaccine at work, but did not remember the details. The patient had a history of D/C, IBS, Colitis, Bell's palsy, PTSD and anxiety. The patient experienced on day 3, i.e. on 23 October 2013, tightness in her chest, tingling in her throat and tongue and mild swelling on the right side. The patient was hospitalized, duration not reported, on unreported dates. Vital signs were reported as okay at an unspecified time. The patient's temperature was not taken. The patient concomitant medications were not reported. Treatment details were not reported. Laboratory tests were not reported. The patient outcome was not recovered. No further information was available at the time of the report. Documents held by sender: None.
Pt near syncope after Moderna vaccine. pt noted to be very warm, pale, nauseated,  tremulous, yet vitals stable. pulse ox normal and  lungs clear. moved pt to private area with q15min vital checks. observed for total of 40 minutes. pt was driven by friend home. Care call 4 hours later, pt's sx have resolved.
received the Pfizer Covid vaccine and tested positive for the virus; received the Pfizer Covid vaccine and tested positive for the virus; This is a spontaneous report from a contactable consumer.  A patient of unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) at single dose for COVID-19 immunisation.  The patient medical history and concomitant medications were not reported.  The patient received the Pfizer Covid vaccine and tested positive for the virus. The outcome of the events was unknown.   Information on the lot/batch number has been requested.
Extreme thirst; Migraine headache; This spontaneous case was reported by a consumer and describes the occurrence of THIRST (Extreme thirst) and MIGRAINE (Migraine headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046A21A) for COVID-19 vaccination.     The patient's past medical history included Migraine since an unknown date. Concomitant products included KETOROLAC TROMETHAMINE (TORADOL) for Migraine.    On 30-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 30-Mar-2021, the patient experienced THIRST (Extreme thirst) and MIGRAINE (Migraine headache). On 30-Mar-2021, THIRST (Extreme thirst) had resolved. At the time of the report, MIGRAINE (Migraine headache) outcome was unknown.            No treatment medication was provided for the events.
Information has been received from an office manager concerning a patient who was in 30's and who on an unspecified date was vaccinated with a dose of PNEUMOVAX 23 (dose, route and lot number not specified). It was reported that the patient experienced adverse reactions on an unspecified date after receiving the PNEUMOVAX 23. The patient complained of redness and little bumps. The patient sought unspecified medical attention. It was given Y-cold compress as a treatment for the adverse event. It was unspecified if the any lab diagnostic studies were performed. At the time of the report, the patient's outcome was unknown. This is one of several reports from the same source. Additional information has been requested.
Pt called Pharmacy on 1-26 stating right arm PNEUMOVAX was administered in was slightly swollen and very sore. Pt did not seek emergency room care - unsure if this is a true adverse reaction.
COVID-19; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 56-year-old male patient received BNT162b2 (BNT162B2), in Nov2021 as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine janssen (COVID-19 VACCINE JANSSEN), on 25Mar2021 as dose number unknown, single (Batch/Lot number: unknown), in right arm for covid-19 immunisation. The patient's relevant medical history included: "COPD" (unspecified if ongoing); "Non-Hodgkins Lymphoma" (unspecified if ongoing), notes: remission for 10 Years. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19. No other medications were received in two weeks. Anti-viral details: Paxlovid for treatment of COVID-19 from 25May2022 to 30May2022. The patient was vaccinated with JJ Mar2021 and received Pfizer booster Nov2021.No known allergies.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
This spontaneous report was received from a licensed practical nurse regarding a 64 year old female patient with concurrent condition of low white blood cell count and urinary tract infection. The patient also had right arm pain the night before administration of PNEUMOVAX 23 and the provider did not think it was an allergic reaction. Her past drugs included nitrofurantoin, azelastine, CIPRO, sulfamethoxazole (+) trimethoprim, fluoxetine, and paroxetine. She had drug reactions/allergies with nitrofurantoin, azelastine, CIPRO, sulfamethoxazole (+) trimethoprim, fluoxetine, and paroxetine. On 22-MAR-2017, the patient was vaccinated with PNEUMOVAX 23 (lot # N000508, expiry 19-OCT-2018) intramuscularly for physical exam, getting up to date on vaccines. Her concomitant therapies included levothyroxine sodium (manufacturer unknown), amoxicillin, and LEXAPRO. On the same day at night, the patient experienced severe right arm pain at the injection site, hyperhidrosis, asthenia, dizziness, and fell twice described as slowly went to the floor, then she got cold and went to a chair, and then felt hot overnight, she experienced severe arm pain with moving her arm and could only abduct the shoulder 20 degrees (injected limb mobility decreased) and then stopped due to pain. She rated her arm pain 3 out of 10 at the injection site. The patient sought medical attention. Treatment included TYLENOL 1000 mg three times a day as needed for pain or ibuprofen 400mg-800mg three times a day as needed for pain. No lab diagnostics/studies were performed. The outcome of hyperhidrosis, asthenia, injection site pain, injected limb mobility decreased, feeling hot, dizziness, pain in extremity, feeling cold and fall was reported as recovered/resolved on an unknown date. Causality for the events was unknown. No PQC was present.
Heart Arrhythmia (irregular heart beat including flutters, rapid heart beat at rest)